Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature. Issue 3 (26th April 2022)

• Record Type: Journal Article
• Authors: Lawrence, Marc R.; Bassal, Mylène; Ramphal, Raveena; Johnston, Donna L.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 44:Issue 3(2022)
• Page Start: e788
• Page End: e791
• Publication Date: 2022-04-26
• Subjects: sinusoidal obstruction syndrome -- veno-occlusive disease -- nontransplant -- defibrotide; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002177
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Sinusoidal obstruction syndrome (SOS), formerly veno-occlusive disease (VOD), in pediatric cancer patients often presents as a complication of hematopoietic stem cell transplantation, and less commonly secondary to nontransplant-associated chemotherapy. Therapy with defibrotide is well-described as standard care for transplant-associated SOS/VOD, but the treatment of nontransplant-associated SOS/VOD is less clear. We report a 3-year-old with relapsed Wilms tumor and recurrent SOS/VOD, with successful use of defibrotide during chemotherapy. A review of pediatric cancer patients with nontransplant-associated SOS/VOD treated with defibrotide revealed 83 patients, and 66 were in remission. This review supports early treatment with defibrotide in patients with nontransplant-associated SOS/VOD.